1036990-21-2

Basic information

• Product Name: 1-(3-broMophenyl)-3-(2,2,2-trifluoroethyl)urea
• Synonyms: 1-(3-broMophenyl)-3-(2,2,2-trifluoroethyl)urea;N-(3-Bromophenyl)-N'-(2,2,2-trifluoroethyl)-urea
• CAS NO: 1036990-21-2
• Molecular Formula: C₉H₈BrF₃N₂O
• Molecular Weight: 297.0718296
• EINECS: -0
• Mol File: 1036990-21-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(3-broMophenyl)-3-(2,2,2-trifluoroethyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-broMophenyl)-3-(2,2,2-trifluoroethyl)urea(1036990-21-2)
• EPA Substance Registry System: 1-(3-broMophenyl)-3-(2,2,2-trifluoroethyl)urea(1036990-21-2)

Safety Data

• Hazardous Substances Data: 1036990-21-2(Hazardous Substances Data)

Usage

Type of compound

Organic urea derivative

Structural features

Bromophenyl group attached
Trifluoroethyl group attached to the urea moiety

Applications

Building block for the synthesis of pharmaceuticals and agrochemicals
Potential anti-cancer agent (inhibits cancer cell growth)
Potential antifungal agent

Interest to researchers and pharmaceutical companies

Significant due to potential therapeutic applications
These properties and contents provide a comprehensive overview of 1-(3-bromophenyl)-3-(2,2,2-trifluoroethyl)urea, highlighting its chemical structure, applications, and significance in the field of medicinal chemistry.

Upstream product

• 753-90-2 trifluoroethylamine 
• 23138-55-8 3-Bromophenyl isocyanate 

Downstream Products

• 874299-21-5 1-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 
• 1434816-70-2 3-(2,2,2-trifluoro-ethyl)-ureido-phenyl-boronic acid 
• 1201653-86-2 N-(2-diethylamino-ethyl)-2-[4-(3-{3-[3-(2,2,2-trifluoro-ethyl)-ureido]-phenyl}-imidazo[1,2-a]pyridin-7-yl)-pyrazol-1-yl]-isobutyramide 
• 1201653-07-7 1-{3-[7-(6-piperidin-1-yl-pyridazin-3-yl)-imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1201652-95-0 1-(3-{7-[5-(tetrahydrofuran-2-yl)-[1,3,4]thiadiazol-2-yl]imidazo[1,2-a]pyridin-3-yl}-phenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1201652-97-2 2-methyl-2-[4-(3-{3-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrazol-1-yl]propionic acid ethyl ester 
• 1201653-24-8 1-(2,2,2-trifluoroethyl)-3-{3-[7-(5-trifluoromethyl[1,3,4]thiadiazol-2-yl)-imidazo[1,2-a]pyridin-3-yl]phenyl}urea 
• 1201653-03-3 2-methyl-2-[4-(3-{3-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrazol-1-yl]propionic acid 
• 1201653-10-2 1-(3-{7-[1-(2-hydroxy-1,1-dimethylethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}phenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1201653-15-7 1-{3-[7-(3-methyl-3H-imidazol-4-ylethynyl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1201653-11-3 1-[3-(7-pyridin-3-ylethynylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1201654-55-8 1-(3-{7-[2-(3-methyl-3H-imidazol-4-yl)-ethyl]-imidazo[1,2-a]pyridin-3-yl}-phenyl)-3-(2,2,2-trifluoro-ethyl)-urea 
• 1201652-99-4 1-[3-(7-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1036991-14-6 1-{3-[7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 

Relevant articles and documents

The Design of Potent, Selective and Drug-Like RGD αvβ1 Small-Molecule Inhibitors Derived from non-RGD α4β1 Antagonists

Up to 45 % of deaths in developed nations can be attributed to chronic fibroproliferative diseases, highlighting the need for effective therapies. The RGD (Arg-Gly-Asp) integrin αvβ1 was recently investigated for its role in fibrotic disease, and thus war

SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION

The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2

BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.